Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Anzu Partners
AddedFeb 13, 2024
UpdatedJul 16, 2026
Anzu Partners

Anzu Partners

Operating

Anzu Partners LLC: A global venture capital firm specializing in industrial technology investments.

Location
Washington, D.C., DC, US
Founded
2014
Firm
Compare
Portfolio
Employees
Website

Investments

EnCharge AI
EnCharge AI

Total Raised

$44.3M

Rounds

2

Series A$22.6MDecember 2023
Series A$21.7MDecember 2022
AM Batteries
AM Batteries
Series B

Total Raised

$60.3M

Rounds

5

Series B$30MDecember 2023
Series A$25MOctober 2022
Aspinity
Aspinity
Series B

Total Raised

$14M

Rounds

8

Series B$5MSeptember 2023
South 8 Technologies
South 8 Technologies

Total Raised

$16.8M

Rounds

7

Series UnknownAugust 2023
Series A$12MApril 2022
XGS Energy
XGS Energy

Total Raised

$33.7M

Rounds

3

Series A$14MMarch 2023
TeraPore Technologies
TeraPore Technologies

Total Raised

$17.7M

Rounds

6

Series Unknown$10MMarch 2023
MedCrypt
MedCrypt

Total Raised

$34.4M

Rounds

6

Series B$25MNovember 2022
Xendee
Xendee

Total Raised

$23M

Rounds

3

Series A$12MJune 2022
Series A$8MNovember 2021
Azumo
Azumo

Total Raised

$58.5M

Rounds

5

Series Unknown$30MMay 2022
Series Unknown$9MDecember 2020
CytoTronics
CytoTronics

Total Raised

$9.3M

Rounds

1

Seed$9.3MApril 2022
BioFlyte
BioFlyte

Total Raised

$12.8M

Rounds

4

Series A$6.1MApril 2022
Codetta
Codetta

Total Raised

$17M

Rounds

2

Series A$15MApril 2022
BioSkryb Genomics
BioSkryb Genomics

Total Raised

$31.5M

Rounds

3

Convertible Note$10MMarch 2022
Convertible Note$10MAugust 2021
6K
6K

Total Raised

$233.3M

Rounds

11

Series C$51MSeptember 2021
NanoCellect Biomedical
NanoCellect Biomedical

Total Raised

$47M

Rounds

5

Series D$20MAugust 2021
InterVenn Biosciences
InterVenn Biosciences

Total Raised

$278.1M

Rounds

5

Series C$201MAugust 2021
Niron Magnetics
Niron Magnetics

Total Raised

$84.6M

Rounds

7

Series Unknown$21.3MJuly 2021
Excision BioTherapeutics
Excision BioTherapeutics

Total Raised

$77.6M

Rounds

8

Series Unknown$60MFebruary 2021
Series AFebruary 2021